Empagliflozin combined with bortezomib in the treatment of heavy and light chain amyloidosis with secondary diabetes: A case report

Current study presented a case of AHL with secondary diabetes following treatment with DARA + CyBorD. For patients with high fasting blood glucose undergoing targeted therapy or chemotherapy, oral glucose tolerance test and glycosylated hemoglobin tests were necessary for the overall health. The difference between free light chain trend changed earlier than 24-hour urine protein, offering guidance for early AHL treatment and enhancing patient quality of life.